Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients

Lung Cancer

Volumn 37, Issue 1, 2002, Pages 57-63

  Brattström, Daniel ^a   Bergqvist, M ^a   Hesselius, P ^a   Larsson, A ^a   Lamberg, K ^a   Wernlund, J ^a   Brodin, O ^a   Wagenius, G ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

bFGF; NSCLC; Prognosis; Recurrent disease; Survival; Tumour volume; VEGF

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; VASCULOTROPIN; ENDOTHELIAL CELL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; LYMPHOKINE; SIGNAL PEPTIDE; TUMOR MARKER; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; THROMBOCYTE COUNT; TUMOR VOLUME; BLOOD; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; SURVIVAL; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; ENDOTHELIAL GROWTH FACTORS; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMAN; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; LYMPHOKINES; MALE; MIDDLE AGE; NEOPLASM RECURRENCE, LOCAL; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL; TUMOR MARKERS, BIOLOGICAL; HUMANS; MIDDLE AGED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035985171     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(02)00027-2     Document Type: Article

References (38)

1. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
2. What is the evidence that tumours are angiogenesis dependent?
3. Relation of neovascularisation to metastasis of non-small-cell lung cancer
4. Tumor angiogenesis in human lung adenocarcinoma
5. Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer
6. Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): Correlation with angiogenesis and survival
7. Relationship between vascularity, age and survival in non-small-cell lung cancer
8. Serum vascular endothelial growth factor is often elevated in disseminated cancer
9. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients
10. Elevated vascular endothelial growth factor levels in sera of patients with lung cancer
11. Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients
12. Vascular endothelial growth factor expression in non-small-cell lung cancer: Prognostic significance in squamous cell carcinoma
13. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer
14. Vascular-specific growth factors and blood vessel formation
15. Identification and characterization of a new splicing variant of vascular endothelial growth factor: VEGF183
16. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis
17. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor
18. The biology of vascular endothelial growth factor
19. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
20. Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia
21. Alternative translation of human fibroblast growth factor 2 mRNA occurs by internal entry of ribosomes
22. The high molecular weight isoforms of basic fibroblast growth factor (FGF-2): An insight into an intracrine mechanism
23. Fibroblast growth factor: Structural and biological properties
24. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo
25. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro
26. Lung (ICD-0 C-34)
27. Prognostic value of vascularity and vascular endothelial growth factor expression in non-small cell lung cancer
28. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis
29. Prognostic value of basic fibroblast growth factor and its receptor (FGFR-1) inpatients with non-small cell lung carcinomas
30. The basic fibroblast growth factor and its receptor in pulmonary adenocarcinomas: An investigation of their expression as prognostic markers
31. Angiogenesis as a prognostic indicator of survival in non-small cell lung carcinoma: A prospective study
32. 'Tumour volume' as a predictor of survival after resection of non-small-cell lung cancer (NSCLC)
33. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: Significance for VEGF measurements and cancer biology
34. Pitfalls in the measurement of circulating vascular endothelial growth factor
35. Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: Which is the optimal specimen?
36. Fibroblast growth factor 2: Its structure and property, paracrine function, tumor angiogenesis, and prostate-related mitogenic and oncogenic functions
37. HIF-1alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis
38. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells